CoChat

Thyroid Hormone Replacement Therapy

Wiersinga, Wilmar M. · 2001 · Hormone Research in Paediatrics
Cited by 148

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

Thyroid hormone replacement has been used for more than 100 years in the treatment of hypothyroidism, and there is no doubt about its overall efficacy. Desiccated thyroid contains both thyroxine (T4) and triiodothyronine (T3); serum T3 frequently rises to supranormal values in the absorption phase, associated with palpitations. Liothyronine (T3) has the same drawback and requires twice-daily administration in view of its short half-life. Synthetic levothyroxine (L-T4) has many advantages: in view of its long half-life, once-daily administration suffices, the occasional missing of a tablet causes no harm, and the extrathyroidal conversion of T4 into T3 (normally providing 80% of the daily T3 production rate) remains fully operative, which may have some protective value during illness. Consequently, L-T4 is nowadays preferred, and its long-term use is not associated with excess mortality. The mean T4 dose required to normalize serum thyroid stimulating hormone (TSH) is 1.6 µg/kg per day, giving rise to serum free T4 (fT4) concentrations that are slightly elevated or in the upper half of the normal reference range. The higher fT4 values are probably due to the need to generate from T4 the 20% of the daily T3 production rate that otherwise is derived from the thyroid gland itself. The daily maintenance dose of T4 varies widely between 75 and 250 µg. Assessment of the appropriate T4 dose is by assay of TSH and fT4, preferably in a blood sample taken before ingestion of the subsequent T4 tablet. Dose adjustments can be necessary in pregnancy and when medications are used that are known to interfere with the absorption or metabolism of T4. A new equilibrium is reached after approximately 6 weeks, implying that laboratory tests should not be done earlier. With a stable maintenance dose, an annual check-up usually suffices. Accumulated experience with L-T4 replacement has identified some areas of concern. First, the bioequivalence sometimes differs among generics and brand names. Second, many patients on T4 replacement have a subnormal TSH. TSH values of ≤0.1 mU/l carry a risk of development of atrial fibrillation and are associated with bone loss although not with a higher fracture rate. It is thus advisable not to allow TSH to fall below – arbitrarily – 0.2 mU/l. Third, recent animal experiments indicate that only the combination of T4 and T3 replacement, and not T4 alone, ensures euthyroidism in all tissues of thyroidectomized rats. It is indeed the experience of many physicians that there exists a small subset of hypothyroid patients who, despite biochemical euthyroidism, continue to complain of tiredness, lack of energy, discrete cognitive disorders and mood disturbances. As organs vary in the extent to which their T3 content is derived from serum T3 or locally produced T3 from T4, these complaints may have a biologic substrate; for example, brain T3 content is largely determined by local deiodinase type II activity. Against this background it is of interest that a number of psychometric scores improved significantly in hypothyroid patients upon substitution of 50 µg of their T4 replacement dose by 12.5 µg T3. Confirmatory studies on this issue are urgently awaited. It could well be that a slow-release preparation containing both T4 and T3 might improve the quality of life, compared with T4 replacement alone, in some hypothyroid patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1159/000048140

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 148

Metadata

Authors
Wiersinga, W. M.
Venue
Hormone Research in Paediatrics
Publisher
S. Karger AG
Published
2001
Volume
56
Issue
Suppl. 1
Pages
74-81
ISSN
  • 1663-2818 (ISSN-L)
  • 1663-2826
OpenAlex
W2165735056
Cited by
148
References
19
FWCI
3.73
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.